CR20200220A - FORMAS SÓLIDAS DE ÁCIDO {[5-(3-CLOROFENIL)-3-HIDROXIPIRIDIN-2-CARBONIL]AMINO}ACÉTICO, COMPOSICIONES, Y USOS DE LAS MISMAS (Divisional 2016-0222) - Google Patents

FORMAS SÓLIDAS DE ÁCIDO {[5-(3-CLOROFENIL)-3-HIDROXIPIRIDIN-2-CARBONIL]AMINO}ACÉTICO, COMPOSICIONES, Y USOS DE LAS MISMAS (Divisional 2016-0222)

Info

Publication number
CR20200220A
CR20200220A CR20200220A CR20200220A CR20200220A CR 20200220 A CR20200220 A CR 20200220A CR 20200220 A CR20200220 A CR 20200220A CR 20200220 A CR20200220 A CR 20200220A CR 20200220 A CR20200220 A CR 20200220A
Authority
CR
Costa Rica
Prior art keywords
solid forms
hydroxypyridine
chlorophenyl
carbonyl
amino
Prior art date
Application number
CR20200220A
Other languages
English (en)
Inventor
James Copp
Anne Luong
Ann NEWMAN
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of CR20200220A publication Critical patent/CR20200220A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>Se proporcionan en la presente formas sólidas que comprenden ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones que comprenden las formas sólidas, métodos para elaborar las formas sólidas y métodos de su uso para el tratamiento de diversas enfermedades y/o trastornos.</p>
CR20200220A 2013-11-15 2014-11-14 FORMAS SÓLIDAS DE ÁCIDO {[5-(3-CLOROFENIL)-3-HIDROXIPIRIDIN-2-CARBONIL]AMINO}ACÉTICO, COMPOSICIONES, Y USOS DE LAS MISMAS (Divisional 2016-0222) CR20200220A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904803P 2013-11-15 2013-11-15
PCT/US2014/065631 WO2015073779A1 (en) 2013-11-15 2014-11-14 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Publications (1)

Publication Number Publication Date
CR20200220A true CR20200220A (es) 2020-11-18

Family

ID=53058045

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20200220A CR20200220A (es) 2013-11-15 2014-11-14 FORMAS SÓLIDAS DE ÁCIDO {[5-(3-CLOROFENIL)-3-HIDROXIPIRIDIN-2-CARBONIL]AMINO}ACÉTICO, COMPOSICIONES, Y USOS DE LAS MISMAS (Divisional 2016-0222)
CR20160222U CR20160222U (es) 2013-11-15 2014-11-14 Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20160222U CR20160222U (es) 2013-11-15 2014-11-14 Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas

Country Status (24)

Country Link
US (7) US9701636B2 (es)
EP (2) EP3578546A1 (es)
JP (5) JP2016537365A (es)
KR (2) KR102381295B1 (es)
CN (2) CN105916502A (es)
AR (2) AR099354A1 (es)
AU (4) AU2014348523B2 (es)
BR (1) BR112016011065B1 (es)
CA (1) CA2930128A1 (es)
CL (1) CL2016001150A1 (es)
CR (2) CR20200220A (es)
DO (1) DOP2016000109A (es)
IL (2) IL245634A0 (es)
MA (1) MA39033A1 (es)
MX (3) MX383715B (es)
MY (1) MY180626A (es)
PE (1) PE20160945A1 (es)
PH (2) PH12021551124A1 (es)
RU (2) RU2021125455A (es)
SA (1) SA516371129B1 (es)
SG (2) SG10201803862UA (es)
TW (5) TWI902264B (es)
WO (1) WO2015073779A1 (es)
ZA (3) ZA201603189B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3357911T3 (pl) 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
NO2686520T3 (es) 2011-06-06 2018-03-17
JP2016521747A (ja) 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 貧血治療のための組成物及び方法
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
MX2016009331A (es) * 2014-01-23 2016-10-26 Akebia Therapeutics Inc Composiciones y metodos para tratar enfermedades oculares.
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
CN105837502A (zh) * 2016-04-05 2016-08-10 湖南欧亚生物有限公司 一种Vadadustat的合成方法
US10703724B2 (en) * 2016-12-13 2020-07-07 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation thereof
WO2019028150A1 (en) 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2020075199A1 (en) 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
US11970450B2 (en) 2018-11-28 2024-04-30 Sandoz Ag Multi-component crystals of an orally available HIF prolyl hydroxylase inhibitor
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021117767A1 (ja) 2019-12-10 2021-06-17 田辺三菱製薬株式会社 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法
IT202000014116A1 (it) 2020-06-12 2021-12-12 Olon Spa Nuovo composto cristallino di vadadustat
CN111825606A (zh) * 2020-06-17 2020-10-27 上海希迈医药科技有限公司 一种伐度司他晶型及其制备方法
KR20230027157A (ko) * 2020-06-19 2023-02-27 아케비아 테라퓨틱스 인코포레이티드 바다두스타트의 약물-약물 상호작용의 조절
GB202011431D0 (en) * 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs
CN114105866A (zh) * 2020-08-26 2022-03-01 广东东阳光药业有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法
CN114105867B (zh) * 2020-09-01 2026-04-28 广东东阳光药业股份有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法
CN115996720A (zh) * 2020-09-04 2023-04-21 广东东阳光药业有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法
EP4274575A1 (en) 2021-01-08 2023-11-15 Akebia Therapeutics Inc. Therapeutic methods using vadadustat
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
US20240148707A1 (en) * 2021-03-01 2024-05-09 Akebia Therapeutics, Inc. Modulation of drug-drug interactions of vadadustat

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
EP0381759A4 (en) 1988-07-25 1990-12-12 Vsesojuzny Kurgansky Nauchny Tsentr "Vosstanovitelnaya Travmatologia I Ortopedia" Traction apparatus for restoring the shape of the hand
TW219933B (es) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DK0650961T3 (da) 1993-11-02 1997-09-15 Hoechst Ag Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
ATE149485T1 (de) 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
CA2253282A1 (en) 1996-04-30 1997-11-06 Hoechst Aktiengesellschaft 3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and their use as drugs
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1024134A4 (en) 1997-10-09 2003-05-14 Ono Pharmaceutical Co DERIVATIVES OF AMINOBUTANIC ACID
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
EP1080075B1 (en) 1998-03-23 2004-08-11 Aventis Pharmaceuticals Inc. Piperididinyl and n-amidinopiperidinyl derivatives
WO2000012517A1 (en) 1998-08-27 2000-03-09 Teva Pharmaceutical Industries Ltd. Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
JP2002531427A (ja) 1998-11-27 2002-09-24 テバ ファーマシューティカル インダストリーズ リミティド セルトラリン塩酸塩多形体
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
JP2003527319A (ja) 1999-08-11 2003-09-16 テバ ファーマシューティカル インダストリーズ リミティド トルセミド多形体
ES2234699T3 (es) 1999-11-17 2005-07-01 Teva Pharmaceutical Industries Ltd. Forma polimorfica de atorvastatina calcio.
IL150187A0 (en) 1999-12-14 2002-12-01 Biogal Pharmaceutical Co Ltd Novel forms of pravastatin sodium
CN1411373A (zh) 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
WO2001044262A1 (en) 1999-12-16 2001-06-21 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph iv
PL356452A1 (en) 1999-12-21 2004-06-28 Teva Pharmaceutical Industries Ltd. Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
AU2261901A (en) 2000-01-11 2001-07-24 Teva Pharma Processes for preparing clarithromycin polymorphs
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
ES2277937T3 (es) 2000-07-27 2007-08-01 Teva Pharmaceutical Industries Ltd. Modafinilo puro y cristalino y su procedimiento de preparacion.
US20020183553A1 (en) 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
KR20030059206A (ko) 2000-10-19 2003-07-07 테바 파마슈티컬 인더스트리즈 리미티드 결정질 벤라팍신 염기 및 벤라팍신 히드로클로라이드의신규한 다형태, 이의 제조 방법
AU2002230935A1 (en) 2000-10-30 2002-05-15 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
KR100704213B1 (ko) 2000-11-03 2007-04-10 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 ｖｉｉ형
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
ES2211373T1 (es) 2001-02-12 2004-07-16 Teva Pharmaceutical Industries Ltd. Nuevas formas cristalinas de oxcarbazepina y procedimientos para su preparacion.
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
JP4590157B2 (ja) 2001-03-21 2010-12-01 アイシス イノヴェイション リミテッド アッセイ、方法および手段
IL158334A0 (en) 2001-04-09 2004-05-12 Teva Pharma Polymorphs of fexofenadine hydrochloride
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
PL374176A1 (en) 2001-08-01 2005-10-03 Biogal Gyogyszergyar Rt Process for purifying n-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethylacetamide(zaleplon) and crystalline forms of zaleplon accessible with the process
HUP0500753A3 (en) 2001-09-07 2006-05-29 Teva Pharma Crystalline forms of valacyclovir hydrochloride
US7629458B2 (en) 2001-10-03 2009-12-08 Teva Pharmaceutical Industries Ltd. Preparation of levofloxacin and hemihydrate thereof
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
CA2465913A1 (en) 2001-11-08 2003-05-15 Judith Aronhime Polymorphs of fexofenadine base
ES2234451T1 (es) 2001-11-14 2005-07-01 Teva Pharmaceutical Industries Ltd. Formas cristalinas y amorfas de losartan potasio y procedimiento para su preparacion.
EP1470116A4 (en) 2001-12-04 2005-04-06 Biogal Gyogyszergyar PREPARATION OF THE ORLISTAT AND CRYSTALLINE FORMS OF THE ORLISTAT
DK2298301T3 (en) 2001-12-06 2018-10-01 Fibrogen Inc MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
IL162461A0 (en) 2001-12-18 2005-11-20 Teva Pharma Polymorphs of clopidogrel hydrogensulfate
CN1625394A (zh) 2001-12-28 2005-06-08 拜奥盖尔药厂有限公司 结晶和无定形莫匹罗星钙的制备方法
MXPA04006909A (es) 2002-01-15 2005-04-19 Teva Pharma Solidos cristalinos de carvedilol y procesos para su preparacion.
CA2475864A1 (en) 2002-02-15 2003-08-28 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
IL164155A0 (en) 2002-03-20 2005-12-18 Teva Pharma Crystalline forms of quetiapine hemifumarate
KR20040093187A (ko) 2002-03-27 2004-11-04 테바 파마슈티컬 인더스트리즈 리미티드 란소프라졸 다형 및 그것의 제조 방법
IL164382A0 (en) 2002-04-11 2005-12-18 Polymorphs and pseudopolymorphs of risedronate sodium
WO2003093217A1 (en) 2002-04-29 2003-11-13 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
KR20040104677A (ko) 2002-04-30 2004-12-10 비오갈 기오기스제르갸르 알티. 신규의 온단세트론 결정 형태, 그 제조 방법, 그 신규의결정 형태를 함유하는 약학 조성물 및 이들을 이용한구역질 치료 방법
CN1665504A (zh) 2002-05-10 2005-09-07 特瓦制药工业有限公司 新晶型的加替沙星
US20040044038A1 (en) 2002-06-10 2004-03-04 Barnaba Krochmal Polymorphic form XVI of fexofenadine hydrochloride
JP2005532364A (ja) 2002-06-14 2005-10-27 テバ ファーマシューティカル インダストリーズ リミティド ガチフロキサシンの新規結晶質形態
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
IL166308A0 (en) 2002-07-18 2006-01-15 Polymorphic forms of nateglinide
US20040022764A1 (en) * 2002-07-31 2004-02-05 Hanan Polansky Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease
PL374993A1 (en) 2002-08-06 2005-11-14 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
EP1532151A2 (en) 2002-08-26 2005-05-25 Teva Pharmaceutical Industries Limited Crystalline solid famciclovir forms i, ii, iii and preparation thereof
US20050043329A1 (en) 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
WO2004050618A2 (en) 2002-11-28 2004-06-17 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
CA2510625A1 (en) 2002-12-12 2004-07-01 Teva Pharmaceutical Industries Ltd. Crystalline forms of gatifloxacin and processes for preparation
AU2003300324A1 (en) 2002-12-24 2004-07-22 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
ATE352305T1 (de) 2003-03-12 2007-02-15 Teva Pharma Stabile pharmazeutische zusammensetzungen mit desloratadine
CA2518999A1 (en) 2003-03-12 2004-09-23 Teva Pharmaceutical Industries Ltd Crystalline and amorphous solids of pantoprazole and processes for their preparation
ES2238022T3 (es) 2003-03-17 2008-11-01 Teva Pharmaceutical Industries Ltd. Poliformos de valsartan.
WO2004103999A1 (en) 2003-05-15 2004-12-02 TEVA Gyógyszergyár Részvénytársaság AZTREONAM β POLYMORPH WITH VERY LOW RESIDUAL SOLVENT CONTENT
KR100871621B1 (ko) 2003-06-02 2008-12-02 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로비르 히드로클로라이드의 신규한 결정질 형태
WO2005016325A2 (en) 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
JP4037898B2 (ja) 2003-06-18 2008-01-23 テバ ファーマシューティカル インダストリーズ リミティド フルバスタチンナトリウム結晶形ｘｉｖ、ｌｘｘｉｉｉ、ｌｘｘｉｘ、ｌｘｘｘ及びｘｘｘｖｉｉ型、それらの調製方法、それらを含有する組成物及びそれらの使用方法
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
US20050054616A1 (en) 2003-07-03 2005-03-10 Judith Aronhime Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
CA2546701C (en) 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
WO2005058819A2 (en) 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
ES2374922T3 (es) 2003-12-16 2012-02-23 Teva Pharmaceutical Industries Ltd. Procedimientos de preparación de formas cristalinas de aripiprazol.
EP1592688A2 (en) 2003-12-18 2005-11-09 Teva Pharmaceutical Industries Ltd. Polymorphic form b2 of ziprasidone base
WO2005075427A2 (en) 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast sodium polymorphs
KR20060117356A (ko) 2004-01-30 2006-11-16 테바 파마슈티컬 인더스트리즈 리미티드 몬테루카스트 유리산 다형체
WO2005077941A2 (en) 2004-02-11 2005-08-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
JPWO2005108370A1 (ja) 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
JP2007532687A (ja) 2004-04-26 2007-11-15 テバ ファーマシューティカル インダストリーズ リミティド フェキソフェナジン塩酸塩の結晶形およびその製造方法
US20060004102A1 (en) 2004-05-07 2006-01-05 Shlomit Wizel Polymorphic forms of nateglinide
KR20080091298A (ko) 2004-05-18 2008-10-09 테바 파마슈티컬 인더스트리즈 리미티드 결정성 고체 팜시클로버의 제조를 위한 건조방법
US7488758B2 (en) 2004-05-20 2009-02-10 Teva Pharmaceutical Fine Chemicals, S.R.L. Levalbuterol hydrochloride polymorph B
MX2007000087A (es) 2004-06-23 2007-11-06 Teva Pharma Acido ibandronico solido y cristalino.
US20060142283A1 (en) 2004-06-29 2006-06-29 Judith Aronhime Crystalline form IV of linezolid
CA2576307A1 (en) 2004-07-01 2006-03-09 Teva Pharmaceutical Industries Ltd. Crystalline forms of 1,24(s)-dihydroxy vitamin d2
US7439373B2 (en) 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
WO2006012499A2 (en) 2004-07-22 2006-02-02 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
CA2568629A1 (en) 2004-07-22 2006-02-23 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetine hydrochloride
EP1930011B1 (en) 2004-08-23 2011-08-17 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium
JP2007513889A (ja) 2004-09-21 2007-05-31 テバ ファーマシューティカル インダストリーズ リミティド 結晶性クロピドグレル臭酸塩及びその調製方法
JP2008514641A (ja) 2004-09-28 2008-05-08 テバ ファーマシューティカル インダストリーズ リミティド 結晶形フェキソフェナジン、およびその調製方法
KR20070072891A (ko) 2004-11-02 2007-07-06 테바 파마슈티컬 인더스트리즈 리미티드 타달라필 결정형 및 이의 제조 방법
WO2006050509A2 (en) 2004-11-03 2006-05-11 Teva Pharmaceutical Industries Ltd. Amorphous and polymorphic forms of telmisartan sodium
EP1812428A2 (en) 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
CA2584430A1 (en) 2004-12-01 2006-06-08 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Methods for preparing pimecrolimus
US20060160785A1 (en) 2004-12-03 2006-07-20 Judith Aronhime Ezetimibe polymorphs
WO2006076562A1 (en) 2005-01-11 2006-07-20 Teva Pharmaceutical Fine Chemicals S.R.L. Process for the preparation of 1-amino-3,5-dimethyladamantane hydrochloride
EP1776049A2 (en) 2005-01-27 2007-04-25 Teva Pharmaceutical Industries Ltd. Duloxetine hcl polymorphs
US20080213404A1 (en) 2005-02-04 2008-09-04 Johnson Randall S Hif Modulating Compounds and Methods of Use Thereof
CA2600010A1 (en) 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof
WO2006091731A2 (en) 2005-02-24 2006-08-31 Teva Pharmaceutical Industries Ltd. Processes for the preparation of linezolid intermediate
WO2006096809A1 (en) 2005-03-08 2006-09-14 Teva Pharmaceutical Industries Ltd. Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine oxalate and the preparation thereof
WO2006098834A2 (en) 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
CN101160281A (zh) 2005-04-06 2008-04-09 特瓦制药工业有限公司 结晶形态的普瑞巴林
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
BRPI0611375A2 (pt) 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
JP4638491B2 (ja) 2005-05-23 2011-02-23 テバ ファーマシューティカル インダストリーズ リミティド シナカルセト塩酸塩結晶フォームｉの調製方法
EP1901622B1 (en) 2005-05-23 2014-07-16 Intercontinental Great Brands LLC Taste potentiator compositions and beverages containing same
AU2006254897A1 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
US20070043099A1 (en) 2005-06-09 2007-02-22 Igor Lifshitz Crystalline forms of carvedilol and processes for their preparation
EP1893559A2 (en) 2005-06-09 2008-03-05 Teva Pharmaceutical Industries Ltd Process for preparation of sertraline hydrochloride form i
MX2007016160A (es) 2005-06-15 2008-03-07 Fibrogen Inc Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.
MX2007002113A (es) 2005-06-22 2007-04-27 Teva Pharma Formas polimorfas de maleato de tegaserod.
US20070154482A1 (en) 2005-09-12 2007-07-05 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007038676A2 (en) 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
WO2007047194A2 (en) 2005-10-11 2007-04-26 Dana-Farber Cancer Institute, Inc. Methods for treating mitf-related disorders
NZ567088A (en) 2005-10-19 2012-06-29 Teva Pharma Crystals of laquinimod sodium, and process for the manufacture thereof
KR100912214B1 (ko) 2005-10-31 2009-08-14 테바 파마슈티컬 인더스트리즈 리미티드 세프디니르 세슘 염의 결정형
US20070191331A1 (en) 2005-10-31 2007-08-16 Kansal Vinod K Crystalline forms of cefdinir potassium salt
US20070167382A1 (en) 2005-11-15 2007-07-19 Nina Finkelstein Crystalline and amorphous forms of telithromycin
EP1828098A1 (en) 2005-11-22 2007-09-05 Teva Pharmaceutical Industries Ltd Crystal forms of cinacalcet hci and processes for their preparation
EP1960363B1 (en) 2005-12-09 2014-01-22 Amgen, Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions and uses thereof
US8080672B2 (en) 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
WO2007081909A2 (en) 2006-01-05 2007-07-19 Teva Gyogyszergyar Zartkoruen Mukodo Forms of dolasetron mesylate and processes for their preparation
US20090023666A1 (en) 2006-01-09 2009-01-22 BTG plc Modulators of Hypoxia Inducible Factor-1 and Related Uses
WO2007082899A1 (en) 2006-01-17 2007-07-26 Vib Vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
US20070225507A1 (en) 2006-01-18 2007-09-27 Gustavo Frenkel Process for preparing a crystalline form of Tegaserod maleate
WO2007084667A2 (en) 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
MX2007012605A (es) 2006-02-21 2008-01-11 Teva Pharma Formas cristalinas novedosas de armodafinil y preparacion de ellas.
JP2007246522A (ja) 2006-02-27 2007-09-27 Teva Pharmaceutical Industries Ltd フルバスタチンナトリウムの新規形及びその調製方法
AR059733A1 (es) 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
WO2007109799A2 (en) 2006-03-23 2007-09-27 Teva Pharmaceutical Industries Ltd. Polymorphs of eszopiclone malate
US20090176825A1 (en) 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
JO2934B1 (en) 2006-06-23 2015-09-15 سميث كلاين بيتشام كوربوريشن Prolyl hydroxylase inhibitors
PL3357911T3 (pl) * 2006-06-26 2022-09-05 Akebia Therapeutics Inc. Inhibitory prolilohydroksylazy i sposoby ich użycia
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
TW200845994A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: prolyl hydroxylase inhibitors
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
JP2010524935A (ja) 2007-04-18 2010-07-22 メルク・シャープ・エンド・ドーム・コーポレイション 新規１，８−ナフチリジン化合物
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
US8309544B2 (en) 2007-05-16 2012-11-13 Merck Sharp & Dohme Corp. Spiroindalones
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
KR20100045480A (ko) 2007-08-10 2010-05-03 크리스탈지노믹스(주) 피리딘 유도체 및 이들의 사용방법
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US8158762B2 (en) 2007-11-08 2012-04-17 Genentech, Inc. Anti-factor B antibodies and their uses
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
JP2011505367A (ja) 2007-11-30 2011-02-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
EA201000915A1 (ru) 2007-11-30 2011-02-28 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Ингибиторы пролилгидроксилазы
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
EP2240178A4 (en) 2007-12-19 2011-10-26 Glaxosmithkline Llc PROLYLHYDROXYLASEHEMMER
WO2009086592A1 (en) 2008-01-04 2009-07-16 Garvan Institute Of Medical Research Method of increasing metabolism
EP2252619B1 (en) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
WO2012170439A1 (en) 2011-06-06 2012-12-13 The Ohio State University Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
NO2686520T3 (es) 2011-06-06 2018-03-17
CN104024227B8 (zh) 2011-07-22 2025-07-29 北京贝美拓新药研发有限公司 抑制脯氨酸羟化酶活性的化合物的晶型及其应用
US8772895B2 (en) 2011-11-28 2014-07-08 Taiwan Semiconductor Manufacturing Company, Ltd. Dark current reduction for back side illuminated image sensor
EP2637274B1 (en) 2012-03-05 2022-05-04 Vetco Gray Scandinavia AS Power cable termination arrangement
JP2016521747A (ja) 2013-06-13 2016-07-25 アケビア セラピューティクス インコーポレイテッドＡｋｅｂｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 貧血治療のための組成物及び方法
MY180626A (en) * 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
MX2016009331A (es) 2014-01-23 2016-10-26 Akebia Therapeutics Inc Composiciones y metodos para tratar enfermedades oculares.
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
US20180065933A1 (en) 2015-03-20 2018-03-08 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
US10703724B2 (en) 2016-12-13 2020-07-07 Crystal Pharmaceutical (Suzhou) Co., Ltd. Crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation thereof
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
JP2023501221A (ja) 2019-10-31 2023-01-18 アケビア セラピューティクス インコーポレイテッド バダデュスタットを使用する治療方法
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Also Published As

Publication number Publication date
ZA202004764B (en) 2025-10-29
CN114890943A (zh) 2022-08-12
PH12016500866A1 (en) 2016-06-20
KR102495018B1 (ko) 2023-02-06
EP3068394A1 (en) 2016-09-21
TW201946625A (zh) 2019-12-16
PE20160945A1 (es) 2016-09-26
PH12021551124A1 (en) 2024-04-29
TWI665190B (zh) 2019-07-11
AU2019202144A1 (en) 2019-04-18
US20220040159A1 (en) 2022-02-10
KR102381295B1 (ko) 2022-03-31
NZ719970A (en) 2022-03-25
MX2016006271A (es) 2017-05-04
AR128483A2 (es) 2024-05-15
AU2022259767B2 (en) 2024-08-15
CL2016001150A1 (es) 2016-12-09
TWI846166B (zh) 2024-06-21
AU2022259767A1 (en) 2022-12-01
US20200345711A1 (en) 2020-11-05
US20150141467A1 (en) 2015-05-21
TW202335670A (zh) 2023-09-16
DOP2016000109A (es) 2016-08-31
BR112016011065A8 (pt) 2020-04-22
JP2016537365A (ja) 2016-12-01
JP2025011163A (ja) 2025-01-23
JP2022176961A (ja) 2022-11-30
KR20220042498A (ko) 2022-04-05
AU2019202144B2 (en) 2020-10-08
TWI902264B (zh) 2025-10-21
AU2020294308B2 (en) 2022-08-11
ZA201905255B (en) 2020-11-25
AU2014348523A1 (en) 2016-06-09
BR112016011065A2 (pt) 2017-08-08
IL245634A0 (en) 2016-06-30
US9701636B2 (en) 2017-07-11
JP2019167353A (ja) 2019-10-03
US20240122910A1 (en) 2024-04-18
TW202435877A (zh) 2024-09-16
AU2020294308A1 (en) 2021-02-18
US11065237B2 (en) 2021-07-20
CA2930128A1 (en) 2015-05-21
SG10202012791TA (en) 2021-01-28
TWI788702B (zh) 2023-01-01
AU2014348523B2 (en) 2019-01-03
US11690836B2 (en) 2023-07-04
US20190290624A1 (en) 2019-09-26
RU2021125455A (ru) 2021-10-05
AR099354A1 (es) 2016-07-20
US20180280365A1 (en) 2018-10-04
JP2020183408A (ja) 2020-11-12
ZA201603189B (en) 2019-11-27
EP3068394A4 (en) 2017-04-26
RU2016123382A (ru) 2017-12-20
US20170258773A1 (en) 2017-09-14
CR20160222U (es) 2016-08-26
TW201605801A (zh) 2016-02-16
SA516371129B1 (ar) 2019-07-28
MX2021007268A (es) 2021-07-15
MX383715B (es) 2025-03-14
US9987262B2 (en) 2018-06-05
TW202126300A (zh) 2021-07-16
BR112016011065B1 (pt) 2022-10-25
NZ759132A (en) 2022-03-25
US10149842B2 (en) 2018-12-11
IL281648A (en) 2021-05-31
MA39033A1 (fr) 2017-11-30
SG10201803862UA (en) 2018-06-28
CN105916502A (zh) 2016-08-31
MX2021001169A (es) 2023-02-10
EP3578546A1 (en) 2019-12-11
US10596158B2 (en) 2020-03-24
WO2015073779A1 (en) 2015-05-21
US12419877B2 (en) 2025-09-23
KR20160083118A (ko) 2016-07-11
MY180626A (en) 2020-12-03

Similar Documents

Publication Publication Date Title
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
HK1216175A1 (zh) 治療性化合物和組合物
HK1232147A1 (zh) 用於治疗纤维化的赛尼克韦罗
EP3715457A3 (en) Modulation of prekallikrein (pkk) expression
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
PH12017500089B1 (en) Aldosterone synthase inhibitors
PH12012501389A1 (en) Hedgehog inhibitors
PH12017500595A1 (en) Aldosterone synthase inhibitors
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2015012720A (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
HK1216721A1 (zh) 治疗肝脏疾病或病状的用途和方法
HK1227294A1 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
HK1227294A (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof